Use of urine neutrophil gelatinase-associated lipocalin for nephrotoxic medication acute kidney injury screening in neonates

J Perinatol. 2024 Dec;44(12):1780-1785. doi: 10.1038/s41372-024-01922-6. Epub 2024 Mar 21.

Abstract

Background: Daily serum creatinine monitoring protocols for acute kidney injury (AKI) are invasive and may lead to surveillance resistance. We aimed to understand if use of urine neutrophil gelatinase-associated lipocalin (uNGAL) could increase high-risk nephrotoxic medication (NTMx) associated AKI screening adherence in neonates.

Methods: Statistical process control methods prior to and post implementation were trended. The primary outcome, screening adherence, was defined as either daily serum creatinine or uNGAL assessment through 2 days post high-risk NTMx exposure.

Results: 1291 monitoring days from the pre-implementation era (4/2020-6/2021) were compared to1377 monitoring days from the post-era (6/2021-10/2022). AKI screening adherence increased (81 to 92%) following implementation of optional uNGAL screening. Urine NGAL accounted for 35% of screening obtained. Use of uNGAL resulted in a 40% reduction in blood sampling for serum creatinine.

Conclusions: Incorporation of uNGAL as a complementary screening tool to serum creatinine demonstrated sustained increased AKI surveillance in our Baby NINJA monitoring program.

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute Kidney Injury* / diagnosis
  • Acute Kidney Injury* / urine
  • Biomarkers* / blood
  • Biomarkers* / urine
  • Creatinine* / blood
  • Creatinine* / urine
  • Female
  • Humans
  • Infant, Newborn
  • Lipocalin-2* / urine
  • Male
  • Neonatal Screening / methods

Substances

  • Lipocalin-2
  • Creatinine
  • LCN2 protein, human
  • Biomarkers